

ORIGINAL ARTICLE

Age-associated changes in regenerative capabilities of mesenchymal stem cell: impact on chronic wounds repair

Bin Yao^{1,2,†}, Sha Huang^{1,3,4,†}, Dongyun Gao^{1,5}, Jiangfan Xie^{1,6}, Nanbo Liu^{1,7} & Xiaobing Fu^{1,3}

1 Key Laboratory of Wound Repair and Regeneration of PLA, The First Affiliated Hospital, General Hospital of PLA, Trauma Center of Postgraduate Medical College, Beijing, P. R. China

2 School of Medicine, Nankai University, Tianjin, China

3 Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA, Beijing, P. R. China

4 Hainan Branch of the Chinese PLA General Hospital, Sanya, P. R. China

5 Department of Oncology, Dongtai People's Hospital, Dongtai, P. R. China

6 Graduate School of Tianjin Medical University, Tianjin, P. R. China

7 Department of Thoracic and Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, P. R. China

Key words

Ageing; Chronic wound; Mesenchymal stem cells (MSCs); Regenerative capabilities

Correspondence to

Prof. S Huang

Key Laboratory of Wound Repair and Regeneration of PLA

The First Affiliated Hospital

General Hospital of PLA

51 Fu Cheng Road

Beijing 100048

P. R. China

E-mail: stellarahuang@sina.com

doi: 10.1111/iwj.12491

Yao B, Huang S, Gao D, Xie J, Liu N, Fu X. Age-associated changes in regenerative capabilities of mesenchymal stem cell: impact on chronic wounds repair. *Int Wound J* 2016; 13:1252–1259

Abstract

Mesenchymal stem cells (MSCs) represent an ideal source of autologous cell-based therapy for chronic wounds. Functional characteristics of MSCs may benefit wound healing by exerting their multi-regenerative potential. However, cell ageing resulting from chronic degenerative diseases or donor age could cause inevitable effects on the regenerative abilities of MSCs. A variety of studies have shown the relationship between MSC ageing and age-related dysfunction, but few associate these age-related impacts on MSCs with their ability of repairing chronic wounds, which are common in the elderly population. Here, we discuss the age-associated changes of MSCs and describe the potential impacts on MSC-based therapy for chronic wounds. Furthermore, critical evaluation of the current literatures is necessary for understanding the underlying mechanisms of MSC ageing and raising the corresponding concerns on considering their possible use for chronic wound repair.

Introduction

Chronic wounds or non-healing wounds remain a clinical challenge in medicine and represent a significant health burden in modern society (1). While standard therapies, including debridement, pressure offloading, dressing regimens, hyperbaric oxygen, antibiotics and topical growth factors, have improved management of wounds and relatively shortened the healing time, there are few therapeutic approaches that effectively reverse the consequence of fibrosis or scar. As the general population continues to age, the number of patients with diabetes and other chronic ageing-related diseases is growing dramatically (2); hence the need for more effective approaches to treat many chronic diseases, including non-healing wounds becomes more important. One promising solution, cell therapy, involving the transplantation of progenitor/stem cells to patients

through local or systemic delivery, has heralded a new area of research for the treatment of wounds with delayed healing (3).

Key Messages

- chronic wounds are an immense social burden in the ageing society
- mesenchymal stem cells (MSCs) with unique regenerative potential serve as a promising treatment for non-healing wounds
- the ageing-related changes in MSCs would certainly affect their regenerative capabilities in chronic wound healing
- the underlying intrinsic and extrinsic mechanisms and corresponding solutions are still limited
- more attention should be paid on improving regeneration potential of ageing MSCs in the treatment of chronic wounds

†These authors contributed equally to this work.




Figure 1 Ageing-induced alterations in mesenchymal stem cells in terms of morphology, proliferation potential, differential potential, telomere and senescence markers.

Mesenchymal stem cells (MSCs) are of great interest because of their unique regenerative potential. The beneficial effect of exogenous MSCs on chronic wound healing had been shown in a variety of animal models and in reported clinical cases (4). However, there appears to be an inevitable link with ageing-associated impact on MSCs and their regenerative capabilities on chronic wound healing. Accumulated data indicate that MSCs from elderly donors or long-term *ex vivo* cultivation show great difference compared with that of young donors in cell morphology, proliferation potential, differentiation potential, telomerase length and activity, as well as special molecular markers (5,6). Moreover, several researchers found that passages of *in vitro* culture share equal importance with donor age when considering the proliferative and differential properties of MSCs (7,8). The decline of regenerative capacity of MSCs is predicted to be caused by cellular ageing (9). Thus, regenerative potential of MSCs might change with age or cultured passages, which suggests a possible limitation in their use for chronic wound repair.

In this review, the ageing-associated changes in MSCs and the related molecular mechanism is summarized. In particular, the impact of these changes on the regenerative capabilities of MSCs and current improvements is described, specifically for chronic wounds.

Age-related changes of MSC features

Age-related changes in MSCs not only mediate cell morphology, proliferation and differentiation, but they also impact on the telomere length, telomerase activity and cellular senescence markers (Figure 1).

Cell morphology

After 20–30 population divisions, MSC morphology shows obviously larger (10) and wider alterations, and the proliferative ability becomes more slow (11) than that of young counterparts. The alterations in cell morphology are typically associated with the Hayflick limitation of cellular senescence (12). Bonab (13) observed that the cytoplasm became granular with many cell inclusions, and debris was formed in the medium after 3 months of *in vitro* culture. Aged MSCs show reduced numbers of spindle-shaped (young) cells in culture, which is exhibited in very early stage of cultivation in MSCs from young donors and is gradually lost with increased cultivation time (10). Notably, transfecting simian vacuolating virus 40 (sv40) (14) or telomerase (15) into MSCs considerably reduces the cell sizes compared with their initial sizes.

Proliferation

The decrease in proliferation capability of ageing cells is manifested in MSCs. Hayflick (16) observed that somatic cells division happens for a limited number of times. The maximal *in vitro* population doubling of MSCs is 30–40, while embryonic stem cells (ESCs) show no such loss (17,18). MSCs from aged donors show a significant decrease in the growth rate (19) and decline in replicative lifespan of ageing somatic cells (20). These results suggest that proliferative capacity is gradually lost with increasing cultured time and donor age.

Differentiation

The capability of MSC differentiation appears to change with age in some cases (17). In chondrocyte induction test, the




Figure 2 Intrinsic and extrinsic molecular triggers for mesenchymal stem cells ageing.

specific genes SOX9, COL2A and AGG sharply decreased with donor age (21). However, the age of the MSC donors had little effect on the ALPase activity or the calcium content for osteogenesis induction and glyceraldehyde-3-phosphate dehydrogenase (GPDH) activity on oil red O staining for adipogenesis induction (22), while another study reported the age-dependent changes of MSCs in relation to the osteogenic potential (23). In addition, with the increased culture time in vitro, the homing ability of transplanted MSCs was severely reduced (24).

Telomere length and telomerase activity

Telomere shortening was found in almost all the ageing cells and was thought to be the first possible mechanism of cellular senescence (25). Cells generally lose proliferation capacity and enter senescence once the telomeres reach a certain length (26). It is reported that telomere shortening happens in MSCs at the rate of 100 bp per every two passages, and in early to late passage cells, the telomere lengths decrease from an average of 10.4 to 7.1 kbp (8). On this basis, the correlation between the dividing capacity and telomere length was studied, in both in vitro and in vivo stem cell ageing (27).

Proliferation was greatly related to telomerase activity but telomerase activity is markedly decreased in somatic cells and other non-embryonic stem cells such as progenitors after 30–40 population doubling (28). Although many studies have detected telomerase activity in MSCs (29), whether MSCs possess telomerase activity is controversial. The divergence in various results obtained in MSCs is due to varying donor age and species (18). Other researchers state that forced telomerase up-regulation could increase the division times and enhance differentiation potential in human MSCs (30), suggesting that

telomerase activity may play a vital role in maintaining the proliferative and differentiation potential of MSCs, and its dysfunction leads to the MSC ageing process.

Cellular senescence markers

The first identified senescence marker is senescence-associated β -galactosidase (SA- β gal); its activity reflects the growing lysosomal compartment that usually occurs in aged cells (12). Recently, more senescence markers were identified: p16^{INK4A}, DEC1, p15^{INK4B} and DCR2 (31) as well as cytological markers: senescence-associated heterochromatin foci (SAHF) and senescence-associated DNA damage foci (SDFs) (32,33). SDFs are abundant in proteins that are related to DNA damage and exist in senescent cells from both mice and humans. Expression of genes that promote cell cycle progression (i.e. c-FOS, cyclin A, cyclin B and PCNA) (34) is suppressed in ageing cells. In the aged MSCs, apoptosis-associated proteins such as p53, caspase 3, caspase 8, caspase 9 down-regulated and Bcl-2, which enhance survival of many cell types, are expressed at a high level (35).

Mechanism of MSC ageing

Although the beneficial effect of exogenous MSCs on chronic wound healing had been evidenced in pre-clinical and clinical studies, autologous treatment with MSCs from older donors appeared to be less effective than application of their younger counterparts (36). These age-related differences remain incompletely understood, as do their functional consequences. Thus, exploring the mechanism of ageing MSCs is vital to indicating age-related MSC impacts on chronic wound healing (Figure 2).

Intrinsic molecular mechanism

Dynamic system dysfunction

Actin turnover significantly decreases in ageing MSCs, leading to the up-regulation of one actin cross-linking protein, transgelin, also the biomarker of ageing, which reduces the actin cytoskeleton dynamics. Actin cytoskeleton translates and processes the external physical stimuli or biochemical molecules into intracellular signals through various growth factors and three-dimensional extracellular matrix structure. Considering this, the actin cytoskeleton could not respond adequately to these factors and was less dynamic. For instance, the mechanical signals regulating bone homeostasis and regeneration are transduced via actin cytoskeleton (37), which may be responsible for the frequent bone-related diseases in elderly patients. By contrast, it is intriguing that mechanical requirements appear to change with age *in vivo* (38). Thus, lower actin dynamics result in regenerative potential decrease of senescent MSCs due to slower and less response to the environmental signals, both biological and mechanical (39).

Energy metabolism defect

Almost all aged cells suffer mitochondrial damage and oxidative impairment (40). Mitochondria are the central organelle supplying energy in the form of ATP. Energy generation, which is accompanied by unstable reactive oxygen species (ROS), may damage both the mitochondrion itself and other components of the cell, which finally causes ageing as a result of damage accumulation (41). Mitochondria are essential for all cells in life and death, and energy support is fundamental for cell differentiation (42). In adult MSCs, early passage cells contain more undifferentiated stem cells that form a significant cluster of mitochondria around the nucleus (43). Frequent self-renewal of stem cells requires more mitochondria resistant to the cellular senescence.

In aged MSCs, expression of several proteins involved in antioxidant defence up-regulate along with decreased antioxidant power, which appears to occur in other cells, such as the increased expression of peroxiredoxins in mouse embryonic fibroblasts with age (23). This might expose cells to higher ROS levels, as well as age-dependent reduced metabolic activities, resulting in insufficient capacity to defend effectively. Thus, despite decreased antioxidative proteins not being the cause for MSC ageing, the molecular damage results from reduced ROS elimination capability which may induce cell dysfunction over time (44).

DNA damage accumulation

Haematopoietic stem cells (HSCs), another kind of multi-potent stem cell, show a dramatic decline in regenerative function activity with age, resulting in degraded blood production and impaired engraftment following transplantation. Flach (45) demonstrated that cycling old HSCs in mice has heightened levels of replication stress associated with cell cycle defects and chromosome gaps or breaks, which are due to decreased expression of mini-chromosome maintenance (MCM) helicase components and altered dynamics of DNA replication forks.

As HSCs share several features with MSCs, such as various differential capability and self-renewing ability, we assume that the DNA damage accumulates because the high replicative stress is a potential driver of functional decline in MSCs from aged donors.

Extrinsic molecular mechanism

Excessive oxidative stress

Cells cultured *in vitro* enter senescence after a certain number of cell divisions. Telomeres can shorten during expansion and excessive oxidative stress can cut down the rate of telomere loss (46). Ageing is considered as a complicated stress response triggered by activation of three main mechanisms: telomere erosion, DNA damage and INK4/ARF locus repression. All of these pathways relate to the tumour suppressors p53 and RB, and are highly consistent with the production of oxidative stress during cell culture, named stress-induced premature senescence (SIPS) (47,48).

Genetic variances

Complete characterization of expanded MSCs is essential in serial passages as ageing imposes restriction on MSC application; especially MSC-based therapies have achieved some success in many disease treatments (49,50). Cai (51) performed a whole-genome sequencing of MSCs in *ex vivo* culture to locate the genetic variances. There are no obvious changes in copy-number variation and low levels of single-nucleotide changes (SNCs) in the initial phase but a significant number of SNCs is found in passage 13. In primary culture and early passage, MSCs had low possibility of SNC mutations but reached a high frequency in passage 13, which clarifies that genomic composition of *ex vivo* MSC cultures tends to be unstable with extended expansion and may be responsible for the ageing process.

Environmental influence from chronic wounds on MSCs

Apart from the systemic ageing, chronic wounds and their pathological microenvironment may negatively affect MSCs itself and their positive properties, and impaired repairing properties may diminish the effectiveness of autologous cell therapy in patients with chronic wounds (52). For example, in the case of chronic wounds in diabetic patients, the high level of glucose induces up-regulation of BAX in MSCs which encourages apoptosis of the stem cells before differentiation or proliferation (53). On the other hand, the advanced glycation end products in the wounds of diabetic patients could inhibit the level of Bcl-2 and increase the caspases, FAS and BAX to promote cell apoptosis by giving rise to higher oxidative stress. Besides, cells near the wound could secrete cytokines such as IL-2, IL-4, IL-7 and so on inducing MSC apoptosis by suppressing Bcl-2 expression. The dysfunction of TGF- β 1 up-regulation after impaired and over-expression of TGF- β 3 in diabetic ulcers also causes limitation in MSCs to prevent their repair capability (54,55). While ample evidence exists that microenvironment of chronic diseases severely affect MSCs in the regenerative capability,

further investigation on their interaction and mechanisms is important for effective clinical application.

Possible impacts of ageing in MSCs on chronic wound healing

The application of MSCs in cell therapy is being studied in several areas of medicine, including chronic wound healing. Badiavas *et al.* directly injected autologous bone marrow derived MSCs (BM-MSCs) to the edge of a wound, and achieved complete closure of the wound (56). Dash and Lu treated 24 patients having chronic ulcers in the lower limb with autologous BM-MSCs intramuscularly and significantly reduced the ulcer size (57,58). The clinical trial carried out by Hernández and coworkers on 22 patients with pressure ulcers due to spinal cord injury showed that injected autologous BM-MSCs topically had a better healing effect compared with traditional surgical treatment (59). Although MSCs show dramatic therapeutic effects on chronic wound healing, more attention should be paid to non-healing wounds that occur in ageing patients. As mentioned above, because donor age or culture senescence impacts the regenerative capability and differential potential of MSCs, it seriously limits the autologous application of MSCs in the ageing population. Therefore, it is imperative to highlight the impact of this relationship between MSC ageing and curative effects on chronic wound healing.

In recent studies, researchers demonstrated that aged adipose tissue derived MSCs are unable to rescue age-associated impairments in cutaneous wound healing because of their significantly compromised ability to support vascular network formation. Through single-cell transcriptional profile analysis, they found a sub-population of MSCs with depleted pro-vascular characteristics (60). Also, there is increasing evidence that aged cells lacked the anti-inflammatory, protective effect due to changes in the expression levels of inflammatory response genes, which indicate that MSCs undergo an age-related decline in their immunomodulatory activity (61). Because angiogenesis dysfunction and inflammation deletion mainly account for chronic wounds, there is no doubt that the therapeutic potential of MSCs in chronic wound healing will be hampered heavily by decreasing these capabilities.

Potential solutions for age-related impacts

Reduced oxygen concentration

A series of molecular and cellular changes occur in MSCs during *in vitro* culture (62). Treatment of MSC lines from donors of various ages with 5% oxygen environment permits the cells to grow more robustly and with less oxidative stress than the traditional 21% oxygen concentration (63). Although the MSCs are obtained from donors of different ages, they share similar cellular fitness, suggesting that low-oxygen concentration may neutralise the negative effects of age, effectively.

Lower temperature of culture

Cell culture in low temperature requires less oxygen consumption, such as a 10% reduction in hybridoma and baby hamster kidney (BHK) cells (64) which directly reduce the radical

level produced by aerobic respiration (65) and decreased culture temperature can also alleviate stress-induced senescence and apoptosis levels (66). Similarly, in MSCs, culturing at a low temperature 32°C shows a significant decline in oxidative damage, radical production and induction of glutathione peroxidase activity by reducing oxidative stress. Culturing temperature also regulates stem cell capacity of self-renewal and maintains the multi-potency of MSCs by raising p53 and p21 levels to suppress differentiation (67,68).

Growth factor addition

MSCs gradually lose differentiation potential in culture as the result of culture stress or *in vitro* senescence. Some batches of foetal bovine serum markedly enhance culture stress or *in vitro* senescence of MSCs. In contrast, MSCs expanded with fibroblast growth factor-2 (FGF-2) maintain their trilineage differentiation potential at high levels throughout many mitotic divisions. Furthermore, FGF-2 markedly enhances MSC proliferation (69). FGF-2 may affect the innate properties of MSCs, but MSCs readily lose multi-potency in culture without FGF-2. Some other studies also used FGF-2 in MSC cultures (70).

Natural environment cultures are beneficial to maintain the properties of MSCs compared with traditional medium. Wharton's jelly extract (WJE) from UC-MSC niche, a commonly used supplement, which is abundant in collagen, fibronectin and insulin-like growth factor I (IGF-I) and basic fibroblast growth factor-b (bFGF) (71), is reported to preserve MSC properties effectively (72). The bottom of culture vessel coated with WJE facilitates in suppressing the MSC senescence through up-regulation of p53 and p16INK4a/pRb expression. Analysis at the molecular level shows decreased intracellular ROS in MSCs (73).

hTERT over-expression

Transfecting with human telomerase reverse transcriptase (hTERT) vector, the telomerase catalytic subunit, *in vitro* culture MSCs enhance genome stability by maintaining mitochondrial physiology to keep the oxygen consumption rate (OCR) and oxidative stress at a low level and normal antioxidant defences such as SOD2, which is significantly over-expressed in ageing cells. hTERT has also been demonstrated to be a transcriptional modulator that promotes metabolism and decreases ROS production (74). In addition, it markedly reduces aneuploidy level and prevents the dysregulation of ploidy-controlling genes through up-regulation of hTERT (75).

Nanog transfection

Pluripotency maintained transcription factor, Nanog (76), reverses the decline of proliferation and differentiation potential in BM-MSCs from adult donors through activation of the TGF- β pathway. The young MSCs express a high level of Nanog and microarray analysis results showed that adult BM-MSCs transfected Nanog close to the neonatal MSCs. It also made genes involved in the cell cycle, DNA replication and DNA damage repair up-regulated, which is definitely

facilitating the proliferation rate and clonogenic capacity. Notably, Nanog will be beneficial in treating cardiovascular diseases that are more likely to happen in elderly patients for its restoration of the myogenic differentiation potential and contractile function of BM-MSC (77). Besides, considering the safety factor, up-regulation of oncogenes may lead to cancer and man-made viral vectors may have potential to infect human cells. Therefore, it is essential to develop safer solutions for these obstacles.

Other approaches for compensation of MSC ageing

Although MSCs have demonstrated a reduced ability to improving chronic wound healing in case of ageing, there is still some compensation to ageing-induced impacts on MSCs. According to previous work, one of the underlying molecular mechanisms of mesenchymal stem cells facilitating chronic wound healing is through the paracrine factors to promote angiogenesis and improve impaired metabolism (78–80). Hence, we assume that up-regulation of the angiogenic factors and IGF-1 in the MSCs could neutralise the negative effects of ageing to some extent. On the other hand, beneficial niche for MSC regulation produced by tissue engineering approaches would be an effective strategy to remedy the potential limitation of MSC ageing. For instance, constructing microparticles with growth factors not only could enhance their interaction with MSCs by increasing its local concentration, but might also ameliorate the therapeutic effects on chronic wounds directly (81).

Summary and future prospective

Despite numerous advances in wound repair, some wounds never heal and become chronic problems that result in significant morbidity and mortality to the patient. Stem cell therapy for these chronic cutaneous wounds has recently emerged on investigation as a potential solution. Especially, MSCs are a promising source of adult progenitor cells as they are easy to isolate and expand and have been shown to differentiate into various cell lineages. However, along with ageing, MSCs are likely to suffer significant loss in number and functionality, resulting in progressive decline in tissue maintenance and regenerative capacity in the long-term (82). On the other hand, the prevalence of chronic wounds usually occurs in the ageing population. Thus, the ageing population has profound impact on MSC regenerative capacity and subsequently on its curative effects.

Age-associated changes in MSCs should be taken into account when they are intended for application in research or for cytotherapy for chronic wound healing. It is required to investigate the entire organism for the internal drivers and extracellular interactions at the molecular, cellular and organ levels, based on the substantial individual variation, with multiple experimental methods. It is also crucial for better approaches to isolate, expand and characterise MSC populations. In addition, resolutions of ageing-related stem cell changes are required to identify specific pathways involved in the activation of MSCs, which is important in the regeneration of a complete and functional tissue.

Future directions for research in this field might focus on optimization of MSC efficiency in the chronic wound context,

both by improving cell function via independent technologies or in combination with tissue engineering designs as well as niche regulation. Moreover, ongoing promising strategies to extend MSC survival and optimise cell delivery continue to emerge, which will improve the regenerative potential of these ageing MSCs in the future.

Acknowledgements

This article was supported in part by the National Nature Science Foundation of China (81121004, 81230041 and 81372066) and the National Basic Science and Development Program (973 Program, 2012CB518105).

The authors declare that they have no competing financial interests.

References

1. Nunan R, Harding KG, Martin P. Clinical challenges of chronic wounds: searching for an optimal animal model to recapitulate their complexity. *Dis Model Mech* 2014;**7**:1205–13.
2. Vogeli C, Shields AE, Lee TA, Gibson TB, Marder WD, Weiss KB, Blumenthal D. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. *J Gen Intern Med* 2007;**22**:391–5.
3. Nuschke A. Activity of mesenchymal stem cells in therapies for chronic skin wound healing. *Organogenesis* 2014;**10**:29–37.
4. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, Leroux MA. Concise review: role of mesenchymal stem cells in wound repair. *Stem Cells Transl Med* 2012;**1**:142–9.
5. Stolzing A, Jones E, McGonagle D, Scutta A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. *Mech Ageing Dev* 2008;**129**:163–73.
6. Asumda FZ, Chase PB. Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. *BMC Cell Biol* 2011;**12**:44.
7. Justesen J, Stenderup K, Eriksen EF, Kassem M. Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. *Calcif Tissue Int* 2002;**71**:36–44.
8. Stenderup K, Justesen J, Clausen C, Kassem M. Ageing is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. *Bone* 2003;**33**:919–26.
9. Raggi C, Berardi AC. Mesenchymal stem cells, ageing and regenerative medicine. *Muscles Ligaments Tendons J* 2012;**2**:239–42.
10. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid ageing of human marrow stromal cells following *in vitro* expansion. *Stem Cells* 2004;**22**:675–82.
11. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. *Proc Natl Acad Sci U S A* 2001;**98**:7841–5.
12. Kulman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. *Genes Dev* 2010;**24**:2463–79.
13. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Ageing of mesenchymal stem cell *in vitro*. *BMC Cell Biol* 2006;**7**:14.
14. Negishi Y, Kudo A, Obinata A, Kawashima K, Hirano H, Yanai N, Obinata M, Endo H. Multipotency of a bone marrow stromal cell line, TBR31-2, established from ts-SV40 T antigen gene transgenic mice. *Biochem Biophys Res Commun* 2000;**268**:450–5.
15. Kobune M, Kawano Y, Ito Y, Chiba H, Nakamura K, Tsuda H, Sasaki K, Dehari H, Uchida H, Honmou O, Takahashi S, Bizen A, Takimoto R, Matsunaga T, Kato J, Kato K, Houkin K, Niitsu Y, Hamada H. Telomerized human multipotent mesenchymal cells can

- differentiate into hematopoietic and cobblestone area-supporting cells. *Exp Hematol* 2003;**31**:715–22.
16. Hayflick L. The limited *in vitro* lifetime of human diploid cell strains. *Exp Cell Res* 1965;**37**:614–36.
 17. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. *Exp Hematol* 2000;**28**:707–15.
 18. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. *Ageing Res Rev* 2006;**5**:91–116.
 19. Mendes SC, Tibbe JM, Veenhof M, Bakker K, Both S, Platenburg PP, Oner FC, de Bruijn JD, van Blitterswijk CA. Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age. *Tissue Eng* 2002;**8**:911–20.
 20. Rubin H. Promise and problems in relating cellular senescence *in vitro* to ageing *in vivo*. *Arch Gerontol Geriatr* 2002;**34**:275–86.
 21. Kanawa M, Igarashi A, Ronald VS, Higashi Y, Kurihara H, Sugiyama M, Saskianti T, Pan H, Kato Y. Age-dependent decrease in the chondrogenic potential of human bone marrow mesenchymal stromal cells expanded with fibroblast growth factor-2. *Cytotherapy* 2013;**15**:1062–72.
 22. Dexheimer V, Mueller S, Braatz F, Richter W. Reduced reactivation from dormancy but maintained lineage choice of human mesenchymal stem cells with donor age. *PLoS One* 2011;**6**:e22980.
 23. Kretlow JD, Jin YQ, Liu W, Zhang WJ, Hong TH, Zhou G, Baggett LS, Mikos AG, Cao Y. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. *BMC Cell Biol* 2008;**9**:60.
 24. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. *Leukemia* 2003;**17**:160–70.
 25. Flores I, Blasco MA. The role of telomeres and telomerase in stem cell aging. *FEBS Lett* 2010;**584**:3826–30.
 26. Parsch D, Fellenberg J, Brummendorf TH, Eschlbeck AM, Richter W. Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. *J Mol Med* 2004;**82**:49–55.
 27. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. *J Clin Invest* 2004;**113**:160–8.
 28. Armstrong L, Lako M, Lincoln J, Cairns PM, Hole N. mTert expression correlates with telomerase activity during the differentiation of murine embryonic stem cells. *Mech Dev* 2000;**97**:109–16.
 29. Filioli Uranio M, Valentini L, Lange-Consiglio A, Caira M, Guaricci AC, L'Abbate A, Catacchio CR, Ventura M, Cremonesi F, Dell'Aquila ME. Isolation, proliferation, cytogenetic, and molecular characterization and *in vitro* differentiation potency of canine stem cells from foetal adnexa: a comparative study of amniotic fluid, amnion, and umbilical cord matrix. *Mol Reprod Dev* 2011;**78**:361–73.
 30. Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, Wang CY. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. *Nat Biotechnol* 2002;**20**:587–91.
 31. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. Tumour biology: senescence in premalignant tumours. *Nature* 2005;**436**:642.
 32. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* 2003;**113**:703–16.
 33. Di Micco R, Cicalese A, Fumagalli M, Dobreva M, Verrecchia A, Pelicci PG, di Fagagna F. DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. *Cell Cycle* 2008;**7**:3601–6.
 34. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. *Nat Rev Mol Cell Biol* 2007;**8**:729–40.
 35. Alt EU, Senst C, Murthy SN, Slakey DP, Dupin CL, Chaffin AE, Kadowitz PJ, Izadpanah R. Ageing alters tissue resident mesenchymal stem cell properties. *Stem Cell Res* 2012;**8**:215–25.
 36. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Phippen AM, Annex BH, Dong C, Taylor DA. Ageing, progenitor cell exhaustion, and atherosclerosis. *Circulation* 2003;**108**:457–63.
 37. Banes A, Lee G, Graff R, Otey C, Archambault J, Tszuzaki M, Elfervig M, Qi J. Mechanical forces and signaling in connective tissue cells: cellular mechanisms of detection, transduction, and responses to mechanical deformation. *Curr Opin Orthop* 2001;**12**:389–96.
 38. Strube P, Sentuerk U, Riha T, Kaspar K, Mueller M, Kasper G, Matziolis G, Duda GN, Perka C. Influence of age and mechanical stability on bone defect healing: age reverses mechanical effects. *Bone* 2008;**42**:758–64.
 39. Kasper G, Mao L, Geissler S, Draycheva A, Trippens J, Kühnisch J, Tschirschmann M, Kaspar K, Perka C, Duda GN, Klose J. Insights into mesenchymal stem cell ageing: involvement of antioxidant defense and actin cytoskeleton. *Stem Cells* 2009;**27**:1288–97.
 40. Li G, Luna C, Liton PB, Navarro I, Epstein DL, Gonzalez P. Sustained stress response after oxidative stress in trabecular meshwork cells. *Mol Vis* 2007;**13**:2282–8.
 41. Navarro A, Torrejon R. Role of nitric oxide on mitochondrial biogenesis during the ovarian cycle. *Front Biosci* 2007;**12**:1164–73.
 42. Rehman J. Empowering self-renewal and differentiation: the role of mitochondria in stem cells. *J Mol Med (Berl)* 2010;**88**:981–6.
 43. Lonergan T, Brenner C, Bavister B. Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. *J Cell Physiol* 2006;**208**:149–53.
 44. Baron W, Metz B, Bansal R, Hoekstra D, de Vries H. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. *Mol Cell Neurosci* 2000;**15**:314–29.
 45. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg EC, Le Beau MM, Stohr BA, Méndez J, Morrison CG, Passequé E. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. *Nature* 2014;**512**:198–202.
 46. Richter T, von Zglinicki T. A continuous correlation between oxidative stress and telomere shortening in fibroblasts. *Exp Gerontol* 2007;**42**:1039–42.
 47. Toussaint O, Weemaels G, Debacq-Chainiaux F, Scharffetter-Kochanek K, Wlaschek M. Artefactual effects of oxygen on cell culture models of cellular senescence and stem cell biology. *J Cell Physiol* 2011;**226**:315–21.
 48. Shay JW, Wright WE. Tissue culture as a hostile environment: identifying conditions for breast cancer progression studies. *Cancer Cell* 2007;**12**:100–1.
 49. Salem HK, Thiernemann C. Mesenchymal stromal cells: current understanding and clinical status. *Stem Cells* 2010;**28**:585–96.
 50. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. *J Hematol Oncol* 2012;**5**:19.
 51. Cai J, Miao X, Li Y, Smith C, Tsang K, Cheng L, Wang QF. Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells. *Stem Cell Reports* 2014;**3**:227–33.
 52. Kuhn NZ, Tuan RS. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. *J Cell Physiol* 2010;**222**:268–77.
 53. Bhan S, Mitra R, Arya AK, Pandey HP, Tripathi K. A study on evaluation of apoptosis and expression of bcl-2-related marker in wound healing of streptozotocin-induced diabetic rats. *ISRN Dermatol* 2013;**2013**:739054.
 54. Berlanga-Acosta J, Schultz GS, López-Mola E, Guillen-Nieto G, García-Siverio M, Herrera-Martínez L. Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing. *BioMed Res Int* 2012;**2013**:15.

55. Arya AK, Tripathi R, Kumar S, Tripathi K. Recent advances on the association of apoptosis in chronic non healing diabetic wound. *World J Diabetes* 2014;**15**:756–62.
56. Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. *J Cell Physiol* 2003;**196**:245–50.
57. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. *Rejuvenation Res* 2009;**12**:359–66.
58. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. *Diabetes Res Clin Pract* 2011;**92**:26–36.
59. Sarasúa JG, López SP, Viejo MA, Basterrechea MP, Rodríguez AF, Gutiérrez AF, Gala JG, Menéndez YM, Augusto DE, Arias AP, Hernández JO. Treatment of pressure ulcers with autologous bone marrow nuclear cells in patients with spinal cord injury. *J Spinal Cord Med* 2011;**34**:301–7.
60. Duscher D, Rennert RC, Januszzyk M, Anghel E, Maan ZN, Whittam AJ, Perez MG, Kosaraju R, Hu MS, Walmsley GG, Atashroo D, Khong S, Butte AJ, Gurtner GC. Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells. *Sci Rep* 2014;**4**:7144.
61. Go AS *et al.* Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. *Circulation* 2013;**127**:e6–245.
62. Stolzing A, Scutt A. Age-related impairment of mesenchymal progenitor cell function. *Aging Cell* 2006;**5**:213–24.
63. Rosová I, Dao M, Capoccia B, Link D, Nolte JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. *Stem Cells* 2008;**26**:2173–82.
64. Chuppa S, Tsai YS, Yoon S, Shackelford S, Rozales C, Bhat R, Tsay G, Matanguihan C, Konstantinov K, Naveh D. Fermentor temperature as a tool for control of high-density perfusion cultures of mammalian cells. *Biotechnol Bioeng* 1997;**55**:338–441.
65. Jorjani P, Ozturk SS. Effects of cell density and temperature on oxygen consumption rate for different mammalian cell lines. *Biotechnol Bioeng* 1999;**64**:349–56.
66. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden DT. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science* 2000;**287**:1804–8.
67. Marcotte R, Wang E. Replicative senescence revisited. *J Gerontol A Biol Sci Med Sci* 2002;**57**:257–69.
68. Stolzing A, Scutt A. Effect of reduced culture temperature on antioxidant defences of mesenchymal stem cells. *Free Radic Biol Med* 2006;**41**:326–38.
69. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, Yoshida E, Takagishi K, Kato Y. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. *Biochem Biophys Res Commun* 2001;**288**:413–9.
70. Bianchi G, Banfi A, Mastrogiacomo M, Notaro R, Luzzatto L, Cancedda R, Quarto R. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. *Exp Cell Res* 2003;**287**:98–105.
71. Sobolewski K, Malkowski A, Bankowski E, Jaworski S. Wharton's jelly as a reservoir of peptide growth factors. *Placenta* 2005;**26**:747–52.
72. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. *Stem Cells* 2007;**25**:646–54.
73. Hao H, Chen G, Liu J, Ti D, Zhao Y, Xu S, Fu X, Han W. Culturing on Wharton's Jelly extract delays mesenchymal stem cell senescence through p53 and p16INK4a/pRb pathways. *PLoS One* 2013;**8**:e58314.
74. Sharma NK, Reyes A, Green P, Caron MJ, Bonini MG, Gordon DM, Holt II, Santos JH. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. *Nucleic Acids Res* 2011;**40**:712–25.
75. Estrada JC, Torres Y, Benguría A, Dopazo A, Roche E, Carrera-Quintanar L, Pérez RA, Enríquez JA, Torres R, Ramírez JC, Samper E, Bernad A. Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. *Cell Death Dis* 2013;**4**:e691.
76. Do JT, Scholer HR. Regulatory circuits underlying pluripotency and reprogramming. *Trends Pharmacol Sci* 2009;**30**:296–302.
77. Han J, Mistriotis P, Lei P, Wang D, Liu S, Andreadis ST. Nanog reverses the effects of organismal aging on mesenchymal stem cell proliferation and myogenic differentiation potential. *Stem Cells* 2012;**30**:2746–59.
78. Gao D, Xie J, Zhang J, Feng C, Yao B, Ma K, Li J, Wu X, Huang S, Fu X. MSC attenuate diabetes-induced functional impairment in adipocytes via secretion of insulin-like growth factor-1. *Biochem Biophys Res Commun* 2014;**452**:99–105.
79. Gao D, Gu C, Wu Y, Xie J, Yao B, Li J, Feng C, Wang J, Wu X, Huang S, Fu X. Mesenchymal stromal cells enhance wound healing by ameliorating impaired metabolism in diabetic mice. *Cytotherapy* 2014;**16**:1467–75.
80. Gu C, Huang S, Gao D, Wu Y, Li J, Ma K, Wu X, Fu X. Angiogenic effect of mesenchymal stem cells as a therapeutic target for enhancing diabetic wound healing. *Int J Low Extrem Wounds* 2014;**13**:88–93.
81. Huang S, Lu G, Wu Y, Jirigala E, Xu Y, Ma K, Fu X. Mesenchymal stem cells delivered in a microsphere-based engineered skin contribute to cutaneous wound healing and sweat gland repair. *J Dermatol Sci* 2012;**66**:29–36.
82. Bellantuono I, Aldahmash A, Kassem M. Ageing of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. *Biochim Biophys Acta* 2009;**1792**:364–70.